Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts. more
Time Frame | ENTA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -16.43% | -2.06% | -0.55% |
1-Month Return | -38.87% | -1.92% | 2.72% |
3-Month Return | -48.64% | -10.4% | 7.66% |
6-Month Return | -50.55% | -4.6% | 10.15% |
1-Year Return | -34.56% | 4.06% | 27.53% |
3-Year Return | -92.59% | 1.94% | 32.31% |
5-Year Return | -90.87% | 36.48% | 89.2% |
10-Year Return | -86.97% | 97.46% | 194.59% |
Sep '20 | Sep '21 | Sep '22 | Sep '23 | Sep '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 122.47M | 97.07M | 86.16M | 79.20M | 67.64M | [{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":79.26,"profit":true},{"date":"2022-09-30","value":70.35,"profit":true},{"date":"2023-09-30","value":64.67,"profit":true},{"date":"2024-09-30","value":55.22,"profit":true}] |
Cost of Revenue | - | - | 2.97M | 2.37M | - | [{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":79.75,"profit":true},{"date":"2024-09-30","value":"-","profit":true}] |
Gross Profit | 122.47M | 97.07M | 83.19M | 79.20M | 67.64M | [{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":79.26,"profit":true},{"date":"2022-09-30","value":67.92,"profit":true},{"date":"2023-09-30","value":64.67,"profit":true},{"date":"2024-09-30","value":55.22,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 96.55% | 100.00% | 100.00% | [{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":96.55,"profit":true},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":100,"profit":true}] |
Operating Expenses | 164.11M | 206.65M | 210.00M | 216.41M | 189.33M | [{"date":"2020-09-30","value":75.83,"profit":true},{"date":"2021-09-30","value":95.49,"profit":true},{"date":"2022-09-30","value":97.04,"profit":true},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":87.48,"profit":true}] |
Operating Income | (41.64M) | (109.57M) | (123.84M) | (137.21M) | (121.69M) | [{"date":"2020-09-30","value":-4163900000,"profit":false},{"date":"2021-09-30","value":-10957300000,"profit":false},{"date":"2022-09-30","value":-12384400000,"profit":false},{"date":"2023-09-30","value":-13720700000,"profit":false},{"date":"2024-09-30","value":-12169100000,"profit":false}] |
Total Non-Operating Income/Expense | 13.09M | 4.01M | 3.23M | 12.42M | - | [{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":30.67,"profit":true},{"date":"2022-09-30","value":24.67,"profit":true},{"date":"2023-09-30","value":94.9,"profit":true},{"date":"2024-09-30","value":"-","profit":true}] |
Pre-Tax Income | (35.02M) | (107.58M) | (122.19M) | (131.00M) | (117.79M) | [{"date":"2020-09-30","value":-3501900000,"profit":false},{"date":"2021-09-30","value":-10757900000,"profit":false},{"date":"2022-09-30","value":-12218800000,"profit":false},{"date":"2023-09-30","value":-13099500000,"profit":false},{"date":"2024-09-30","value":-11778800000,"profit":false}] |
Income Taxes | 1.15M | (28.58M) | (433.00K) | 2.82M | (1.74M) | [{"date":"2020-09-30","value":40.73,"profit":true},{"date":"2021-09-30","value":-1013.22,"profit":false},{"date":"2022-09-30","value":-15.35,"profit":false},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":-61.79,"profit":false}] |
Income After Taxes | (36.17M) | (79.00M) | (121.75M) | (133.82M) | - | [{"date":"2020-09-30","value":-3616800000,"profit":false},{"date":"2021-09-30","value":-7899600000,"profit":false},{"date":"2022-09-30","value":-12175500000,"profit":false},{"date":"2023-09-30","value":-13381600000,"profit":false},{"date":"2024-09-30","value":"-","profit":true}] |
Income From Continuous Operations | (36.17M) | (79.00M) | (121.75M) | (133.82M) | - | [{"date":"2020-09-30","value":-3616800000,"profit":false},{"date":"2021-09-30","value":-7899600000,"profit":false},{"date":"2022-09-30","value":-12175500000,"profit":false},{"date":"2023-09-30","value":-13381600000,"profit":false},{"date":"2024-09-30","value":"-","profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}] |
Net Income | (36.17M) | (79.00M) | (121.75M) | (133.82M) | (116.05M) | [{"date":"2020-09-30","value":-3616800000,"profit":false},{"date":"2021-09-30","value":-7899600000,"profit":false},{"date":"2022-09-30","value":-12175500000,"profit":false},{"date":"2023-09-30","value":-13381600000,"profit":false},{"date":"2024-09-30","value":-11604500000,"profit":false}] |
EPS (Diluted) | (1.82) | (3.91) | (5.91) | (6.37) | (5.48) | [{"date":"2020-09-30","value":-182,"profit":false},{"date":"2021-09-30","value":-391,"profit":false},{"date":"2022-09-30","value":-591,"profit":false},{"date":"2023-09-30","value":-637,"profit":false},{"date":"2024-09-30","value":-548,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ENTA | |
---|---|
Cash Ratio | 4.31 |
Current Ratio | 5.21 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ENTA | |
---|---|
ROA (LTM) | -17.18% |
ROE (LTM) | -59.64% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ENTA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.66 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.34 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ENTA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1.81 |
P/B | 1.04 |
Price/FCF | NM |
EV/R | 0.83 |
EV/Ebitda | NM |
PEG | NM |
Enanta Pharmaceuticals Inc (ENTA) share price today is $5.85
Yes, Indians can buy shares of Enanta Pharmaceuticals Inc (ENTA) on Vested. To buy Enanta Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ENTA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Enanta Pharmaceuticals Inc (ENTA) via the Vested app. You can start investing in Enanta Pharmaceuticals Inc (ENTA) with a minimum investment of $1.
You can invest in shares of Enanta Pharmaceuticals Inc (ENTA) via Vested in three simple steps:
The 52-week high price of Enanta Pharmaceuticals Inc (ENTA) is $17.8. The 52-week low price of Enanta Pharmaceuticals Inc (ENTA) is $5.7.
The price-to-earnings (P/E) ratio of Enanta Pharmaceuticals Inc (ENTA) is
The price-to-book (P/B) ratio of Enanta Pharmaceuticals Inc (ENTA) is 1.04
The dividend yield of Enanta Pharmaceuticals Inc (ENTA) is 0.00%
The market capitalization of Enanta Pharmaceuticals Inc (ENTA) is $129.92M
The stock symbol (or ticker) of Enanta Pharmaceuticals Inc is ENTA